97 related articles for article (PubMed ID: 20392999)
1. Rapamycin-mediated FOXO1 inactivation reduces the anticancer efficacy of rapamycin.
Abdelnour-Berchtold E; Cerantola Y; Roulin D; Dormond-Meuwly A; Demartines N; Dormond O
Anticancer Res; 2010 Mar; 30(3):799-804. PubMed ID: 20392999
[TBL] [Abstract][Full Text] [Related]
2. Targeting the JNK signaling pathway potentiates the antiproliferative efficacy of rapamycin in LS174T colon cancer cells.
Benoit M; Dormond-Meuwly A; Demartines N; Dormond O
J Surg Res; 2011 May; 167(2):e193-8. PubMed ID: 21324487
[TBL] [Abstract][Full Text] [Related]
3. Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1alpha axis.
Pencreach E; Guérin E; Nicolet C; Lelong-Rebel I; Voegeli AC; Oudet P; Larsen AK; Gaub MP; Guenot D
Clin Cancer Res; 2009 Feb; 15(4):1297-307. PubMed ID: 19190131
[TBL] [Abstract][Full Text] [Related]
4. Rapamycin-resistant and torin-sensitive mTOR signaling promotes the survival and proliferation of leukemic cells.
Park S; Sim H; Lee K
BMB Rep; 2016 Jan; 49(1):63-8. PubMed ID: 26497580
[TBL] [Abstract][Full Text] [Related]
5. Orexin A protects cells from apoptosis by regulating FoxO1 and mTORC1 through the OX1R/PI3K/AKT signaling pathway in hepatocytes.
Ju SJ; Zhao Y; Chang X; Guo L
Int J Mol Med; 2014 Jul; 34(1):153-9. PubMed ID: 24807827
[TBL] [Abstract][Full Text] [Related]
6. Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors.
Takeuchi H; Kondo Y; Fujiwara K; Kanzawa T; Aoki H; Mills GB; Kondo S
Cancer Res; 2005 Apr; 65(8):3336-46. PubMed ID: 15833867
[TBL] [Abstract][Full Text] [Related]
7. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
Amornphimoltham P; Patel V; Sodhi A; Nikitakis NG; Sauk JJ; Sausville EA; Molinolo AA; Gutkind JS
Cancer Res; 2005 Nov; 65(21):9953-61. PubMed ID: 16267020
[TBL] [Abstract][Full Text] [Related]
8. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity.
Jacinto E; Facchinetti V; Liu D; Soto N; Wei S; Jung SY; Huang Q; Qin J; Su B
Cell; 2006 Oct; 127(1):125-37. PubMed ID: 16962653
[TBL] [Abstract][Full Text] [Related]
9. The effects of mTOR-Akt interactions on anti-apoptotic signaling in vascular endothelial cells.
Dormond O; Madsen JC; Briscoe DM
J Biol Chem; 2007 Aug; 282(32):23679-86. PubMed ID: 17553806
[TBL] [Abstract][Full Text] [Related]
10. Transcription factor Foxo1 represses T-bet-mediated effector functions and promotes memory CD8(+) T cell differentiation.
Rao RR; Li Q; Gubbels Bupp MR; Shrikant PA
Immunity; 2012 Mar; 36(3):374-87. PubMed ID: 22425248
[TBL] [Abstract][Full Text] [Related]
11. Rapamycin regulates Akt and ERK phosphorylation through mTORC1 and mTORC2 signaling pathways.
Chen XG; Liu F; Song XF; Wang ZH; Dong ZQ; Hu ZQ; Lan RZ; Guan W; Zhou TG; Xu XM; Lei H; Ye ZQ; Peng EJ; Du LH; Zhuang QY
Mol Carcinog; 2010 Jun; 49(6):603-10. PubMed ID: 20512842
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells.
Grünwald V; DeGraffenried L; Russel D; Friedrichs WE; Ray RB; Hidalgo M
Cancer Res; 2002 Nov; 62(21):6141-5. PubMed ID: 12414639
[TBL] [Abstract][Full Text] [Related]
13. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.
Sun SY; Rosenberg LM; Wang X; Zhou Z; Yue P; Fu H; Khuri FR
Cancer Res; 2005 Aug; 65(16):7052-8. PubMed ID: 16103051
[TBL] [Abstract][Full Text] [Related]
14. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo.
Johnsen JI; Segerström L; Orrego A; Elfman L; Henriksson M; Kågedal B; Eksborg S; Sveinbjörnsson B; Kogner P
Oncogene; 2008 May; 27(20):2910-22. PubMed ID: 18026138
[TBL] [Abstract][Full Text] [Related]
16. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
17. Nuclear forkhead box O1 controls and integrates key signaling pathways in hepatocytes.
Naïmi M; Gautier N; Chaussade C; Valverde AM; Accili D; Van Obberghen E
Endocrinology; 2007 May; 148(5):2424-34. PubMed ID: 17303659
[TBL] [Abstract][Full Text] [Related]
18. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways.
Han S; Khuri FR; Roman J
Cancer Res; 2006 Jan; 66(1):315-23. PubMed ID: 16397245
[TBL] [Abstract][Full Text] [Related]
19. FOXO1-mediated activation of Akt plays a critical role in vascular homeostasis.
Dharaneeswaran H; Abid MR; Yuan L; Dupuis D; Beeler D; Spokes KC; Janes L; Sciuto T; Kang PM; Jaminet SS; Dvorak A; Grant MA; Regan ER; Aird WC
Circ Res; 2014 Jul; 115(2):238-251. PubMed ID: 24874427
[TBL] [Abstract][Full Text] [Related]
20. Quercetin induces growth arrest through activation of FOXO1 transcription factor in EGFR-overexpressing oral cancer cells.
Huang CY; Chan CY; Chou IT; Lien CH; Hung HC; Lee MF
J Nutr Biochem; 2013 Sep; 24(9):1596-603. PubMed ID: 23618529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
